SE447246B - P-kloroacetofenonoximderivat och farmaceutiska kompositioner innehallande nemnda derivat - Google Patents
P-kloroacetofenonoximderivat och farmaceutiska kompositioner innehallande nemnda derivatInfo
- Publication number
- SE447246B SE447246B SE8001073A SE8001073A SE447246B SE 447246 B SE447246 B SE 447246B SE 8001073 A SE8001073 A SE 8001073A SE 8001073 A SE8001073 A SE 8001073A SE 447246 B SE447246 B SE 447246B
- Authority
- SE
- Sweden
- Prior art keywords
- oxime
- derivatives
- chloroacetophenone
- represent
- pyrrolidino
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- -1 alkyl radical Chemical class 0.000 claims description 12
- 230000000202 analgesic effect Effects 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 150000002923 oximes Chemical class 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- PITONXVHZQRZMF-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-(2-pyrrolidin-1-ylethoxy)ethanimine Chemical compound C=1C=C(Cl)C=CC=1C(C)=NOCCN1CCCC1 PITONXVHZQRZMF-UHFFFAOYSA-N 0.000 claims description 3
- 230000001754 anti-pyretic effect Effects 0.000 claims description 3
- 239000002221 antipyretic Substances 0.000 claims description 3
- 239000012458 free base Substances 0.000 claims description 3
- 229910052736 halogen Inorganic materials 0.000 claims description 3
- 150000002367 halogens Chemical class 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- BUZYGTVTZYSBCU-UHFFFAOYSA-N 1-(4-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Cl)C=C1 BUZYGTVTZYSBCU-UHFFFAOYSA-N 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 239000003434 antitussive agent Substances 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 229920006395 saturated elastomer Polymers 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 150000007513 acids Chemical class 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- QWHQEOJLPHIUON-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-(2-morpholin-4-ylethoxy)ethanimine Chemical compound C=1C=C(Cl)C=CC=1C(C)=NOCCN1CCOCC1 QWHQEOJLPHIUON-UHFFFAOYSA-N 0.000 claims 1
- ZWDXBSDPAOLKCD-UHFFFAOYSA-N 2-[1-(4-chlorophenyl)ethylideneamino]oxy-n,n-diethylethanamine Chemical compound CCN(CC)CCON=C(C)C1=CC=C(Cl)C=C1 ZWDXBSDPAOLKCD-UHFFFAOYSA-N 0.000 claims 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940125716 antipyretic agent Drugs 0.000 claims 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- KAXTWDXRCMICEQ-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethylidene]hydroxylamine Chemical class ON=C(C)C1=CC=C(Cl)C=C1 KAXTWDXRCMICEQ-UHFFFAOYSA-N 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 150000003254 radicals Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 10
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 5
- 229910021529 ammonia Inorganic materials 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZEWPZWZBVHCPOR-UHFFFAOYSA-N 2-[1-(4-chlorophenyl)ethylideneamino]oxy-n,n-dimethylethanamine Chemical compound CN(C)CCON=C(C)C1=CC=C(Cl)C=C1 ZEWPZWZBVHCPOR-UHFFFAOYSA-N 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940090044 injection Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VKPPFDPXZWFDFA-UHFFFAOYSA-N 2-chloroethanamine Chemical class NCCCl VKPPFDPXZWFDFA-UHFFFAOYSA-N 0.000 description 1
- USSIQXCVUWKGNF-UHFFFAOYSA-N 6-(dimethylamino)-4,4-diphenylheptan-3-one Chemical compound C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 USSIQXCVUWKGNF-UHFFFAOYSA-N 0.000 description 1
- 229910002016 Aerosil® 200 Inorganic materials 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 229920003084 Avicel® PH-102 Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000111 LD50 Toxicity 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- ZEHGKSPCAMLJDC-UHFFFAOYSA-M acetylcholine bromide Chemical compound [Br-].CC(=O)OCC[N+](C)(C)C ZEHGKSPCAMLJDC-UHFFFAOYSA-M 0.000 description 1
- 229940080018 acetylcholine injection Drugs 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR7903617A FR2449081A1 (fr) | 1979-02-13 | 1979-02-13 | Nouveaux derives de p-chloroacetophenone oxime, leur preparation et leur application en tant que medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SE447246B true SE447246B (sv) | 1986-11-03 |
Family
ID=9221905
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8001073A SE447246B (sv) | 1979-02-13 | 1980-02-12 | P-kloroacetofenonoximderivat och farmaceutiska kompositioner innehallande nemnda derivat |
| SE8001073D SE8001073L (sv) | 1979-02-13 | 1980-02-12 | P-kloracetofenonoximderivat och forfarande for framstellning derav |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8001073D SE8001073L (sv) | 1979-02-13 | 1980-02-12 | P-kloracetofenonoximderivat och forfarande for framstellning derav |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US4342763A (enExample) |
| JP (1) | JPS5849539B2 (enExample) |
| AR (1) | AR222522A1 (enExample) |
| AT (1) | AT369730B (enExample) |
| BE (1) | BE881589A (enExample) |
| BG (1) | BG34034A3 (enExample) |
| CA (1) | CA1140127A (enExample) |
| CH (1) | CH644098A5 (enExample) |
| CS (1) | CS216651B2 (enExample) |
| DD (1) | DD149063A5 (enExample) |
| DE (1) | DE3004972C2 (enExample) |
| EG (1) | EG14161A (enExample) |
| ES (1) | ES487971A1 (enExample) |
| FI (1) | FI71136C (enExample) |
| FR (1) | FR2449081A1 (enExample) |
| GB (1) | GB2043063B (enExample) |
| GR (1) | GR65624B (enExample) |
| HU (1) | HU183057B (enExample) |
| IL (1) | IL59315A (enExample) |
| NL (1) | NL187974C (enExample) |
| PL (1) | PL221840A1 (enExample) |
| PT (1) | PT70792A (enExample) |
| RO (1) | RO77526A (enExample) |
| SE (2) | SE447246B (enExample) |
| YU (1) | YU41502B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2435830A (en) * | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Oxime ether compounds for the treatment of conditions associated with food uptake |
| JP4936905B2 (ja) * | 2007-01-10 | 2012-05-23 | 株式会社リコー | プロセスカートリッジ及び画像形成装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3692835A (en) * | 1967-04-05 | 1972-09-19 | Jan Van Dijk | Pharmacologically active amino-ethyl oximes |
| BE754448A (fr) * | 1969-08-08 | 1971-02-05 | Choay Sa | Nouveaux medicaments a base d'imines substituees, nouvelles imines substituees et leurs procedes de fabrication |
-
1979
- 1979-02-13 FR FR7903617A patent/FR2449081A1/fr active Granted
-
1980
- 1980-01-24 ES ES487971A patent/ES487971A1/es not_active Expired
- 1980-02-05 AT AT0062380A patent/AT369730B/de not_active IP Right Cessation
- 1980-02-05 IL IL59315A patent/IL59315A/xx unknown
- 1980-02-06 US US06/119,104 patent/US4342763A/en not_active Expired - Lifetime
- 1980-02-06 PL PL22184080A patent/PL221840A1/xx unknown
- 1980-02-06 PT PT70792A patent/PT70792A/pt not_active IP Right Cessation
- 1980-02-07 GB GB8004154A patent/GB2043063B/en not_active Expired
- 1980-02-07 AR AR279900A patent/AR222522A1/es active
- 1980-02-07 BE BE0/199297A patent/BE881589A/fr not_active IP Right Cessation
- 1980-02-07 CA CA000345342A patent/CA1140127A/fr not_active Expired
- 1980-02-08 GR GR61169A patent/GR65624B/el unknown
- 1980-02-08 YU YU334/80A patent/YU41502B/xx unknown
- 1980-02-08 CH CH101880A patent/CH644098A5/fr not_active IP Right Cessation
- 1980-02-09 EG EG72/80A patent/EG14161A/xx active
- 1980-02-11 RO RO80100151A patent/RO77526A/ro unknown
- 1980-02-11 BG BG046561A patent/BG34034A3/xx unknown
- 1980-02-11 DE DE3004972A patent/DE3004972C2/de not_active Expired
- 1980-02-11 FI FI800413A patent/FI71136C/fi not_active IP Right Cessation
- 1980-02-11 DD DD80218997A patent/DD149063A5/de unknown
- 1980-02-12 SE SE8001073A patent/SE447246B/sv not_active IP Right Cessation
- 1980-02-12 SE SE8001073D patent/SE8001073L/xx not_active Application Discontinuation
- 1980-02-12 HU HU80312A patent/HU183057B/hu not_active IP Right Cessation
- 1980-02-12 NL NLAANVRAGE8000880,A patent/NL187974C/xx not_active IP Right Cessation
- 1980-02-12 CS CS80939A patent/CS216651B2/cs unknown
- 1980-02-13 JP JP55016494A patent/JPS5849539B2/ja not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4225610A (en) | Immunoactivators derived from amino thiazoles | |
| JP4415075B2 (ja) | 炎症性腸疾患のためのカッパーアヘン製剤作働薬 | |
| US3932638A (en) | Compositions and methods for wound healing | |
| US5085867A (en) | Method for treating gastric ulcer with sulglycotide and hydrophilic polymer | |
| EP0092647B1 (en) | New active compounds in the treatment of ulcers and skin allergy symptoms | |
| IE891908L (en) | Novel esters | |
| SE447246B (sv) | P-kloroacetofenonoximderivat och farmaceutiska kompositioner innehallande nemnda derivat | |
| US3936450A (en) | Anti-inflammatory agents and method for their preparation | |
| CA1118781A (en) | 2-benzothiazolyl oxamic acid and esters | |
| US2278123A (en) | Antispasmodics | |
| KR940009179A (ko) | 벤조푸란 유도체, 그의 제조 방법, 그를 함유한 제약조성물 및 그의 의약으로서의 용도 | |
| GB2034587A (en) | Pharmaceutical compositions | |
| SE446530B (sv) | Nya derivat av 6-metoxi-2-acetylnaftalenoxim, vilka derivat har analgetiska, antipyretiska och anti-inflammatoriska egenskaper | |
| DE2525250C2 (de) | N,N'-Phenylendioxamsäureester, Verfahren zu deren Herstellung sowie pharmazeutische Präparate, die diese Verbindungen enthalten | |
| PT87031B (pt) | Processo de preparacao de compostos de 4-fenilpiperidina e de composicoes farmaceuticas que os contem | |
| JPH0651669B2 (ja) | 抗炎症及び鎮痛活性を有する化合物及び組成物 | |
| US4218447A (en) | Acyl derivatives of hellebrigenin | |
| WO2005102320A1 (fr) | Medicament pour traiter des infections virales | |
| DE2634191A1 (de) | Gem-diarylverbindungen und sie enthaltende arzneimittel | |
| GB1564091A (en) | M-acyloxanilates and compositions containing them | |
| US4189497A (en) | Method of treating arthritic disease | |
| JPS6354338A (ja) | ４−フエニル−４−オキソ−２−ブテン酸の新誘導体、その製造法、薬剤としての使用及びそれを含有する組成物 | |
| US3973037A (en) | Hydratropic acid derivatives in the treatment of non-inflammatory allergic reactions | |
| JPH0377898A (ja) | シアロシルコレステロールからなる筋ジストロフィー症治療剤 | |
| KR830002274B1 (ko) | p-클로로아세토페논 옥심의 신규유도체의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8001073-9 Effective date: 19940910 |